Shots:

• The P-III study involves assesing the safety- efficacy- immunogenicity & PK of BAT1806 vs Actemra/RoActemra (tocilizumab) in 621 patients with the mod. to sev. RA with inadequate response to methotrexate
• The study met its 1EPs that demonstrated equivalent efficacy and comparable safety profile to the Actemra/RoActemra. The 1EP of the study was ACR20
• Biogen has exclusive regulatory- manufacturing- and commercial rights of BAT1806 in all countries excluding China (include Hong Kong- Macau- and Taiwan). In 2021- companies collaborated under which Bio-Thera will receive $30M payment following the achievement of P-III satisfactory results and is eligible for milestones along with royalties

  Ref: Globe Newswire | Image:Biogen